Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. (2nd September 2021)

• Record Type: Journal Article
• Authors: Loilome, Watcharin; Dokduang, Hasaya; Suksawat, Manida; Padthaisong, Sureerat
• Is Part Of: Expert opinion on investigational drugs. Volume 30:Number 9(2021)
• Page Start: 985
• Page End: 1006
• Publication Date: 2021-09-02
• Subjects: Cholangiocarcinoma -- precision medicine -- chemotherapy -- amino acid transporter-based inhibitor -- immunotherapy -- drug repurposing -- tumor heterogeneity -- cancer stem cells -- tumor microenvironment -- multiomics study -- precision medicine; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2021.1955102
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction: Cholangiocarcinoma (CCA) is a malignant tumor of bile duct epithelium with the highest incidence found in Thailand. Some patients are considered suitable for adjuvant therapy and surgical resection is currently the curative treatment for CCA patients. Tumor recurrence is still a hurdle after treatment; hence, finding novel therapeutic strategies to combat CCA is necessary for improving outcome for patients. Areas covered: We discuss targeted therapies and other novel treatment approaches which include protein kinase inhibitors, natural products, amino acid transporter-based inhibitors, immunotherapy, and drug repurposing. We also examine the challenges of tumor heterogeneity, cancer stem cells (CSCs), the tumor microenvironment, exosomes, multiomics studies, and the potential of precision medicine. Expert opinion: Because CCA is difficult to diagnose at the early stage, the traditional treatment approaches are not effective for many patients and most tumors recur. Consequently, researchers are exploring multi-aspect molecular carcinogenesis to uncover molecular targets for further development of novel targeted drugs.